Popular search terms:
Search Results
34 results found-
CSL Seqirus, a business of CSL (ASX: CSL), has been selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to fill and finish additional pre-pandemic vaccine doses as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS).
https://www.cslseqirus.ca/news/avian -
CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government’s outbreak and preparedness response.
https://www.cslseqirus.ca/news/csl-seqirus-announces-us-government-award-in-response-to-avian-influenza -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news -
CSL Seqirus welcomes the federal government’s announcement highlighting the creation of a new agency, Health Emergency Readiness Canada (HERC), ensuring that Canada is prepared for future health emergencies.
https://www.cslseqirus.ca/news/health-emergency-readiness-canada -
Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.
https://www.cslseqirus.ca/news/news-archives -
CSL Seqirus is Fully Prepared to Implement the WHO’s Trivalent Influenza Vaccines Strain Selection for the 2025/26 Canadian Influenza Season
https://www.cslseqirus.ca/news/canadian-audience-only -
Seqirus Ready to Reinforce Canada’s Influenza Pandemic Preparedness Plans
https://www.cslseqirus.ca/news/news-archives/seqirus-ready-to-reinforce-canadas--influenza-pandemic-preparedness-plans -
CSL Seqirus, a business of CSL (ASX: CSL), today announced new data from five studies reinforcing the importance of seasonal influenza vaccination and exhibiting the benefits of cell-based influenza vaccines among people aged 6 months to 64 years.
https://www.cslseqirus.ca/news/idweek-2024 -
FLUAD® Influenza vaccine (surface antigen, inactivated, adjuvanted with MF59® is now preferentially recommended by the Comité sur l’immunisation du Québec for adults 65 years of age and older.
https://www.cslseqirus.ca/news/fluad-adjuvanted-flu-vaccines-for-quebec-seniors-csl-seqirus-welcomes-the-ciq-recommendation -
CSL Seqirus, a business of CSL (ASX: CSL), announced data from a range of real-world evidence (RWE) studies, highlighting the important role influenza vaccination plays in protecting public health.
https://www.cslseqirus.ca/news/options